Home  >  News
you can get e-magazine links on WhatsApp.Click here
Corporate + Font Resize -

Eli Lilly ensures baricitinib's access in India for restricted emergency use as Covid-19 therapy via donations and licensing pacts

Our Bureau, Bengaluru
Tuesday, May 4, 2021, 17:15 Hrs  [IST]

Eli Lilly and Company to help Covid-19 patients in India is offering donations of baricitinib to the Indian government through direct relief. It is simultaneously working with local Indian pharmaceutical companies to execute royalty-free voluntary licensing agreements to accelerate the manufacturing and distribution of the medicine in India during the pandemic.

An initial donation of 400,000 baricitinib tablets is being made immediately for eligible hospitalized Covid-19 patients in India. The company will work urgently to increase the quantity of donated product multifold over the coming weeks.

The MNC pharma major received emergency use authorization by the Central Drugs Standard Control Organization, for baricitinib. It is an oral medication currently registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs.

"With the Covid-19 crisis devastating India, hospitals are overwhelmed by the number of cases and patients need access to potentially life-saving treatments such as baricitinib," said David A. Ricks, chairman and CEO, Eli Lilly.

Baricitinib is authorized for use under an Emergency Use Authorization (EUA) in combination with remdesivir, for treatment of suspected or laboratory confirmed Covid-19 in hospitalized adults and pediatric patients 2 years of age or older, requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).


* Name :     
* Email :    
  Website :  
Copyright © 2016 Saffron Media Pvt. Ltd |